Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen | Zendy

Saleh Mostafa F. M. | Zendy; Saunthararajah Yogen | Zendy

Open Access

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen

Author(s) -

Saleh Mostafa F. M.,

Saunthararajah Yogen

Publication year - 2017

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.1221

Subject(s) - medicine , decitabine , pyoderma gangrenosum , regimen , myelodysplastic syndromes , myeloid leukemia , malignancy , deoxycytidine , dermatology , cancer , gemcitabine , bone marrow , disease , biochemistry , gene expression , chemistry , dna methylation , gene

Key Clinical Message Pyoderma gangrenosum ( PG ) is a morbid necrotizing neutrophilic dermatoses for which current treatments are inadequate. Here, we describe the use of a novel noncytotoxic regimen of the deoxycytidine analog decitabine to treat underlying myeloid malignancy causing PG , to thereby produce safe and effective resolution of extensive PG .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research